Indofarma Tbk (INAF) - Total Liabilities
Based on the latest financial reports, Indofarma Tbk (INAF) has total liabilities worth Rp1.47 Trillion IDR (≈ $86.28 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Indofarma Tbk generate cash to assess how effectively this company generates cash.
Indofarma Tbk - Total Liabilities Trend (2000–2024)
This chart illustrates how Indofarma Tbk's total liabilities have evolved over time, based on quarterly financial data. Check Indofarma Tbk (INAF) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Indofarma Tbk Competitors by Total Liabilities
The table below lists competitors of Indofarma Tbk ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wing Yip Food Holdings Group Limited American Depositary Shares
NASDAQ:WYHG
|
USA | $42.79 Million |
|
Jindo.Co. Ltd
KO:088790
|
Korea | ₩25.95 Billion |
|
Teaminvest Private Group Ltd
AU:TIP
|
Australia | AU$46.12 Million |
|
Pulsenmore Ltd
TA:PULS
|
Israel | ILA45.83 Million |
|
Shradha Infraprojects Limited
NSE:SHRADHA
|
India | Rs2.41 Billion |
|
Desane Group Holdings Ltd
AU:DGH
|
Australia | AU$35.11 Million |
|
Gryphon Digital Mining Inc.
NASDAQ:GRYP
|
USA | $17.19 Million |
|
Honey Badger Silver Inc
V:TUF
|
Canada | CA$791.94K |
Liability Composition Analysis (2000–2024)
This chart breaks down Indofarma Tbk's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Indofarma Tbk worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Indofarma Tbk's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Indofarma Tbk (2000–2024)
The table below shows the annual total liabilities of Indofarma Tbk from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Rp1.76 Trillion ≈ $103.26 Million |
+12.67% |
| 2023-12-31 | Rp1.56 Trillion ≈ $91.64 Million |
+8.04% |
| 2022-12-31 | Rp1.45 Trillion ≈ $84.83 Million |
-3.72% |
| 2021-12-31 | Rp1.50 Trillion ≈ $88.10 Million |
+17.19% |
| 2020-12-31 | Rp1.28 Trillion ≈ $75.18 Million |
+45.96% |
| 2019-12-31 | Rp879.00 Billion ≈ $51.51 Million |
-7.05% |
| 2018-12-31 | Rp945.70 Billion ≈ $55.41 Million |
-5.76% |
| 2017-12-31 | Rp1.00 Trillion ≈ $58.80 Million |
+24.52% |
| 2016-12-31 | Rp805.88 Billion ≈ $47.22 Million |
-14.36% |
| 2015-12-31 | Rp941.00 Billion ≈ $55.14 Million |
+43.36% |
| 2014-12-31 | Rp656.38 Billion ≈ $38.46 Million |
-6.73% |
| 2013-12-31 | Rp703.72 Billion ≈ $41.24 Million |
+30.68% |
| 2012-12-31 | Rp538.52 Billion ≈ $31.55 Million |
+6.49% |
| 2011-12-31 | Rp505.71 Billion ≈ $29.63 Million |
+19.64% |
| 2010-12-31 | Rp422.69 Billion ≈ $24.77 Million |
-1.54% |
| 2009-12-31 | Rp429.31 Billion ≈ $25.16 Million |
-35.85% |
| 2008-12-31 | Rp669.22 Billion ≈ $39.21 Million |
-6.78% |
| 2007-12-31 | Rp717.87 Billion ≈ $42.06 Million |
+76.62% |
| 2006-12-31 | Rp406.45 Billion ≈ $23.82 Million |
+60.29% |
| 2005-12-31 | Rp253.58 Billion ≈ $14.86 Million |
-5.47% |
| 2004-12-31 | Rp268.26 Billion ≈ $15.72 Million |
-27.11% |
| 2003-12-31 | Rp368.02 Billion ≈ $21.56 Million |
-10.68% |
| 2002-12-31 | Rp412.04 Billion ≈ $24.14 Million |
+40.06% |
| 2001-12-31 | Rp294.19 Billion ≈ $17.24 Million |
+19.78% |
| 2000-12-31 | Rp245.61 Billion ≈ $14.39 Million |
-- |
About Indofarma Tbk
PT Indofarma Tbk, together with its subsidiaries, manufactures and sells pharmaceutical products in Indonesia and internationally. The company offers laboratory, pharmaceutical, and health glass equipment; orthopedic and prosthetic equipment; medical and dental equipment; and reparation of Irradiation / X-ray, electromedical and electrotherapy equipment. It also trades in laboratory, pharmaceutic… Read more